Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
January 30 2024 - 8:00AM
Business Wire
Agilent Technologies Inc. (NYSE: A) today announced an agreement
with Incyte that will bring together Agilent’s expertise and proven
track record in the development of companion diagnostics (CDx) to
support the development and commercialization of Incyte’s
hematology and oncology portfolio.
The value of the companion diagnostics market is predicted to
expand to nearly US $14B by 2030,1 driven in part by the power of
these tests to inform treatment decisions for a growing range of
cancers and other chronic diseases. Developed for use with targeted
therapeutics, companion diagnostics are used to evaluate expression
of biomarkers and identify patients that are likely to benefit from
treatment with the targeted therapeutic products.
The agreement between Agilent and Incyte allows the companies to
collaborate on CDx development programs. This will enable Agilent
to continue to expand its companion diagnostics portfolio with
novel biomarkers and Incyte to leverage Agilent’s expertise in IVD
assay development, global regulatory approvals, and
commercialization to support clinical trials as well as the
potential registration and commercialization of CDx in the United
States and Europe.
Paul Beresford, vice president and general manager of Agilent’s
Companion Diagnostics Division, discussed the significance of the
partnership: “Leveraging the power of companion diagnostics, we are
strategically transforming the treatment paradigm for a broad
spectrum of cancers. By working together, Agilent and Incyte hope
to expedite the development of innovative precision medicine
products, potentially paving the way for enhanced patient health
outcomes.”
Jeff Jackson, group vice president of Translational Medicine at
Incyte added: “Agilent’s expertise in the development of companion
diagnostics is impressive, as is their regulatory and
commercialization record. We are excited about the collaboration
and look forward to working together to innovate in support of
patients.”
With an established and growing portfolio of world-class
chemistries and technologies, Agilent has a strong track record as
a provider and partner for companion diagnostics development across
the precision oncology sector. This year, Agilent celebrates the
25th anniversary of HercepTest, a critical tool for assessing HER2
expression in breast cancers. Since the launch of HercepTest,
Agilent has introduced several additional CDx tests. Among these,
the PDL-1 IHC 22C3 franchise has been particularly successful,
offering a continually expanding range of tests for assessing PDL-1
expression.
- Source: Companion Diagnostics Market Size USD 13.74 Billion by
2030
(www.vantagemarketresearch.com/industry-report/companion-diagnostics-market-2021)
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insights and innovation that help our customers bring
great science to life. Agilent’s full range of solutions includes
instruments, software, services, and expertise that provide trusted
answers to our customers' most challenging questions. The company
generated revenue of $6.85 billion in fiscal 2022 and employs
approximately 18,000 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
please subscribe to the Agilent Newsroom. Follow Agilent on
LinkedIn and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240130873870/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2024 to May 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From May 2023 to May 2024